Description

Letrozol CRCA Coated Tablets 2.5 mg. №90

Ingredients

Each tablet contains 2.5 mg of Letrozole.

Dosage

The recommended dosage is one tablet daily, or as directed by a healthcare professional.

Indications

Letrozol CRCA is indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women.

Contraindications

Do not use Letrozol CRCA if you are pregnant, breastfeeding, or allergic to letrozole.

Directions

Swallow the tablet whole with a glass of water, with or without food.

Scientific Evidence

Letrozole, the active ingredient in Letrozol CRCA, is a potent aromatase inhibitor that has shown significant efficacy in the treatment of hormone receptor-positive breast cancer. Clinical studies have demonstrated that Letrozole is superior to tamoxifen in terms of disease-free survival and overall survival rates in postmenopausal women with early-stage breast cancer.

Additional Information

Letrozol CRCA coated tablets are formulated for controlled release, ensuring a steady concentration of the drug in the body for optimal therapeutic effect. It is important to follow the prescribed dosage and regimen to achieve the best treatment outcomes.

Consult your healthcare provider for more information on the use of Letrozol CRCA and to discuss any potential side effects or interactions with other medications.